Status:
UNKNOWN
Beovu Experience UZ Leuven
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
Brief Summary
Reporting early real-world clinical data of consecutive patients on the use of Beovu® (brolucizumab) intravitreal injections in patients with neovascular age-related macular degeneration.
Detailed Description
Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. It received FDA approval for the treatment of neovascular age-related macular...
Eligibility Criteria
Inclusion
- Diagnosis of neovascular age-related macular degeneration
- Partial response on current anti-VEGF treatment or unability to prolong the treatment interval beyond 6 or 8 weeks
Exclusion
- 1\. Any form of previous intraocular inflammation 2. Any form of previous inflammatory reaction after anti-VEGF treatment 3. Functionally monophthalmic patients 4. Any sign of active intraocular inflammation
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT05220085
Start Date
December 1 2020
End Date
April 1 2022
Last Update
February 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZLEUVEN
Leuven, Belgium, 3000